Breast Cancer

The implementation of genetic testing for patients prescribed medications associated with progressive multifocal leukoencephalopathy is likely to improve safety outcomes.

Ribociclib plus endocrine therapy demonstrates a reduction in the risk of disease recurrence in patients with HR+/HER2- early breast cancer.

Drugs such as pembrolizumab, sacituzumab govitecan, and datopotamab deruxtecan all have growing bodies of evidence illustrating which patients with cancer are most likely to benefit and in which settings.

3D biofabrication models reflect increasing global awareness of the ethics of preclinical studies and an increased need for determining therapeutic efficacy differences.

Therapy effectively treats cells harboring HR deficiencies, including those of specific types of ovarian, breast cancers.

Most patients used nonproprietary drugs, which may contribute to the reduction of out-of-pocket costs for the treatment of invasive breast cancer.

The vaccine targets a protein that is no longer found after lactation in normal aging tissues but is present in most triple-negative breast cancers.

The approach was based on previous research suggesting that foods rich in carotenoids, lycopene, certain B vitamins, and omega 3 fatty acids improved fatigue in survivors of breast cancer.

Metformin may accelerate paclitaxel’s actions on cell replication in endometrial cancer.

Incidence of regional tumor recurrence in patients with HR–positive breast cancer did not significantly differ between patients who received post operational radiotherapy.

Numerous clinical trials are investigating the next generation of PARPi.

Cancer screening rates were still below the expected rates of return in both 2021 and 2022.

Patients with triple-negative breast cancer treated with veliparib had statistically significantly longer survival than those given placebo.

Ultra-processed food consumption linked to an increased risk of developing and dying from ovarian cancer and breast cancer.

Findings suggest cancer may have overtaken cardiovascular disease as a leading cause of death in individuals with type 2 diabetes.

CAR T cell gel eliminated the residual tumor cells in almost all mouse models, allowing the mice to survive when they otherwise would have succumbed to tumor recurrence.

Sarah McDonald, cancer survivor and author of The Cancer Channel, discusses her experience battling 2 different unrelated cancers and the value oncology pharmacists could have provided with a greater presence on her care team.

The head of the CAR T cell antibody can recognize and target the growth factor in its tumor microenvironment.

Significant study results may help inform clinical practice strategies.

The report highlights the growth of personalized medicines with improved efficacy for rare, previously untreatable diseases.

In 10 states, the data showed more than 26% of women had limited accessibility to mammography, primarily in the Rocky Mountains and the South.

Lions and tigers and zebras oh my! Expert says precision medicine helps identify unique “zebras” (cancers), but it is increasingly difficult to keep up with new treatment indications across a broad range of cancers.

Trends in treatment development involve more targeted, safe, and efficacious therapies.

Lack of access to novel therapies, especially within the cancer space, initiated the road to patient navigation.

OP-1250 and palbociclib showed “enhanced suppression of tumor growth” in preclinical mouse model studies, according to expert who presented his findings in a poster at the San Antonio Breast Cancer Symposium 2022.

Expert sits with Pharmacy Times to share the promising results of a study that evaluated the safety of a new antibody drug conjugate with radiation therapy.

Efficacy and safety profile in combination with alpelisib is comparable to that reported in the BYLieve and SOLAR-1 clinical trials, according to a poster presentation at the San Antonio Breast Cancer Symposium.

Dawn L. Hershman, MD, MS, Columbia University Medical Center, New York, NY, presents her findings at the 2022 San Antonio Breast Cancer Symposium.

Researchers discovered the most common single gene mutation that causes treatment-resistance in first- line ER-positive or HER2-negative breast cancer treatment with a CDK4/6 inhibitor.

Clinical trial results found that second-line treatment with trastuzumab deruxtecan led to significantly longer overall survival compared with trastuzumab emtansine.